Opioids and Other Controlled Substances: Minimizing the Risks in Prescribing, Dispensing and Administering
Recording of a 90-minute CLE webinar with Q&A
This CLE webinar will guide healthcare counsel on the legal challenges and liability risks facing practitioners and pharmacists related to prescribing and dispensing controlled substances. The panel will discuss the enforcement environment and steps to minimize legal risks.
- Legal challenges facing providers
- Regulatory environment
- Prescribing via telemedicine
- Electronic prescriptions/E-authentication
- Steps to minimize risks of liability/risk management strategies
- Prescription drug monitoring
- Federal laws
- State laws
- State licensing authorities
The panel will review these and other key issues:
- What safeguards should physicians and other prescribing providers put in place in their prescription practice to minimize opioid-related liability risks?
- How is the current enforcement environment impacting prescribing practices?
- Does prescribing opioids using telemedicine create legal risks for healthcare providers?
Kerry B. Harvey
Mr. Harvey has deep experience in leading legal teams tasked with solving complex problems. As U. S. Attorney for the... | Read More
Mr. Harvey has deep experience in leading legal teams tasked with solving complex problems. As U. S. Attorney for the Eastern District of Kentucky, he placed special emphasis on financial fraud, healthcare fraud, and public corruption. Mr. Harvey served Kentucky as GC of its Cabinet for Health and Family Services and Acting Inspector General. As the Commonwealth’s top healthcare lawyer, he represented Kentucky in reimbursement methodology litigation, CON matters and licensing issues. Mr. Harvey’s private practice experience includes representation of healthcare providers, financial institutions and public officials. He has served on the Board of Director’s of Kentucky’s largest owner/operator of hospitals, as well as publicly traded financial institutions. In addition to extensive litigation experience, Mr. Harvey has advised a number of businesses as outside GC concerning compliance, governance and regulatory issues.Close
Lindsay P. Holmes
Ms. Holmes focuses her practice on regulatory and transactional matters primarily in the healthcare and life sciences... | Read More
Ms. Holmes focuses her practice on regulatory and transactional matters primarily in the healthcare and life sciences industries. She has experience advising clients on FDA regulatory matters including drug, device, dietary supplement and cosmetic issues, as well as matters related to 503B outsourcing facilities and the Drug Quality and Security Act. Ms. Holmes also helps pharmacy clients navigate state licensing and pharmacy practice act issues. Additionally, she has experience counseling clients on data privacy and security matters, fraud and abuse, and Medicare Part D.Close
Ms. Mazina offers extensive experience to healthcare providers in the areas of government investigations, including... | Read More
Ms. Mazina offers extensive experience to healthcare providers in the areas of government investigations, including DEA, FDA, HHS, boards of pharmacy and medical boards; third-party audits and licensing involving PBMs, Medicaid, and Medicare; compliance with board of pharmacy, medical board, FDA and DEA regulations, PBM contracts and manuals, HIPAA and state privacy laws, and Anti-Kickback Statutes and false claims; as well as license defense. She is a frequent author and lecturer on minimizing risk in relation to controlled substances, among other matters.Close
Dennis A. Wichern
Prescription Drug Consulting
Mr. Wichern is a 30-year veteran of the DEA who formerly managed the Chicago Field Division. He currently assists... | Read More
Mr. Wichern is a 30-year veteran of the DEA who formerly managed the Chicago Field Division. He currently assists healthcare providers in navigating through the myriad of federal laws and regulations concerning prescription drugs. Mr. Wichern is a recognized expert on the dangers of the prescription drug epidemic and routinely speaks to healthcare providers to identify methods to better safeguard their practices and reduce the professional and operational risks emanating from these threats. He was the first to develop CME and CLE programs addressing MAT and pain prescribing safeguards, federal regulatory and DEA compliance, and drug destruction.Close